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LETTERS TO THE EDITOR 
Interleukin-lO concentration in children 
undergoing cardiopulmonary bypass 
To the Editor: 
We read with interest the article by Seghaye and 
associates, 3 "Interleukin-10 Release Related to Cardio- 
pulmonary Bypass in Infants Undergoing Cardiac Opera- 
tions." 
We also evaluated the interleukin-10 (IL-10) concentra- 
tion in 13 children (age range 1.2 to 12.7 years, average 5.1 
years) undergoing cardiac operations for congenital heart 
disease. Arterial blood samples were obtained before, im- 
mediately after, and 30 minutes after protamine administra- 
tion and then 3 hours after and 18 hours after cardiopulmo- 
nary bypass (CPB). Serum was separated immediately by 
centrifugation and specimens were stored at -20°C until 
use. The serum concentration of IL-8 was measured by 
means of a commercially available enzyme-linked immu- 
nosorbent assay (Sumitomokinzoku Bioassay Laboratories, 
Kanagawa, Japan). In our study, IL-10 concentrations before 
CPB (247.4 + 205.1 pg/ml) increased immediately after CPB 
(349.5 -+ 252.7 pg/ml, p < 0.01), peaked 30 minutes after 
protamine administration (628.5 + 258.0 pg/ml), then grad- 
ually decreased, and there was no second release of IL-10 
(Fig. 1). The course of IL-10 in our study was similar to that 
of IL-8 in our study and in their study. 
In our study, however, there were some differences 
from their study. First, patients in our study were older 
than those in their study, whereas duration of CPB and 
aortic crossclamping (86.6 -+ 40.2 minutes and 49.2 _+ 27.8 
minutes, respectively) were similar to those of their study. 
Second, IL-10 concentrations before CPB in eight of 13 
children were already higher than 200 pg/ml with no 
explanationl Third, in all patients,/3-methasone (3 mg/kg) 
was used for priming. 
We cannot explain why the course of IL-f0 in our study 
was so different from the course in their study, and we 
would like to investigate further. 
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Fig. 1. Course of IL-10 before and after CPB in !3 
children. Values are expressed by mean _+ standard 
deviation. *Significant difference in IL-10 concentration 
compared with baseline values (p < 0.05). A, Before CPB; 
B, immediately after CPB; C, 30 minutes after protamine 
administration; D, 3 hours after CPB; E, 18 hours after 
CPB. 
Reply to the Editor: 
The report by Sugita and associates, in comparison with 
our observation, shows some differences with respect o 
the mean prebypass values of interleukin-10 (IL-10) and 
the course of this natural antiinftammatory cytokine dur- 
ing and after cardiopulmonary b pass (CPB). 
Although the sensitivity of the assay that was used in the 
study by Sugita and associates for IL-10 determinations is 
not specified, it seems obvious that some of the patients 
had abnormally elevated IL-10 levels before CPB. In 
accordance with other reports in adults ~'2 we find low 
prebypass IL-10 concentrations in our patients. The ele- 
vated prebypass IL-10 concentrations measured by Sugi- 
ta's group raise the question of whether preoperative 
infectious or inflammatory disease was present in some of 
the patients of the series investigated. Furthermore, as 
tumor necrosis factor-c~ is thought o be the main inductor 
for IL-10 production, 3 it would be interesting to know the 
preoperative levels of tumor necrosis factor-a in the 
patients with abnormally high IL-10 concentrations as 
well. The preoperative administration of drugs known to 
enhance IL-10 synthesis (e.g., chlorpromazine, corticoste- 
roids) 4 should also be taken into account for the interpre- 
tation of the results reported. 
In our opinion, the different course of IL-10 observed 
by Sugita's group with a release showing its peak in the 
early postoperative period could be ascribed to the ad- 
ministration of corticosteroids in the priming solution. 
Indeed, by inhibiting the release of proinflammatory 
cytokines during CPB and by increasing IL-10 produc- 
tion, ~ corticosteroids might have limited both the magni- 
tude and uration of the inflammatory reaction induced 
by CPB and might have advanced the p ak concentration 
of IL-10 to an earlier time. Finally, as we showed in our 
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study, the degree of hypothermia during CPB should also 
be considered a factor influencing the production of 
IL-10. 
For all the reasons discussed herein, the release of the 
antiinflammatory c tokine IL-10 in response to the in- 
flammatory stress of CPB is a process largely dependent 
on the immunomodulatory effect of the inflammatory, 
pharmacologic, and physical variables that are related to 
the protocol adopted for cardiac operations. 
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Atrial natriuretie peptide release after cardiac 
transplantation 
To the Editor: 
We read with interest the article "Atrial Natriuretic 
Peptide Release at Rest and With Exercise After Cardiac 
Transplantation With the Bicaval Technique" by Jahnke 
and associates (J Thorac Cardiovas Surg 1995;110:1600- 
5). We have been interested in the significance of the high 
levels of natriuretic peptides released after cardiac trans- 
plantation. Our findings, 1presented before the New York 
meeting of The International Society for Heart and Lung 
Transplantation i  March 1996, correlate in some aspects 
with the findings of Jahnke and his associates. 
High levels of plasma atrial natriuretic peptide (ANP) 
and ventricular expression of brain natriuretic peptide 
(BNP) have been identified after standard orthotopic 
cardiac transplantation. 2-4It was postulated that the large 
atrial mass after transplantation maintains the secretion of 
the high levels of ANP. 5 The significance of high levels of 
BNP after cardiac transplantation is unknown. 4 We have 
studied 40 ambulatory, randomly selected patients 6 
months to 1 year after cardiac transplantation. Plasma 
levels of both ANP and BNP were elevated in patients 
who had bicaval orthotopic heart transplantation with 
small atrial mass (ANP, 197.9 _+ 30.22 pg/ml; BNP, 7.4 _+ 
7.1 pg/ml [mean ± standard eviation]) and in patients 
who had standard orthotopic heart transplantation and 
large atrial mass (ANP, 191.3 _+ 44.6.88 pg/ml; BNP, 
10.9 ± 7.6 pg/ml) in comparison with normal healthy 
volunteers (ANP, 95.7 +- 30.1 pg/ml; BNP, 1.18 _+ 0.18; 
p < 0.0001 andp < 0.0001, respectively ). ANP levels were 
not significantly different between the bicaval and the 
standard group. These data suggest hat high levels of 
ANP were synthesized and secreted by the transplanted 
denervated human heart, regardless of the transplantation 
technique. Despite the near complete denervation with 
the bicaval technique, ANP secretion continued, support- 
ing the findings of Jahnke and colleagues. Lower mean 
systemic pressure and high serum urea content are asso- 
ciated with higher levels of ANP (p < 0.05), which can be 
the result of the vasodilator potential of ANP. BNP levels 
were significantly higher in the standard group (10.9 -+ 7.6 
pg/ml) than in the bicaval group (7.4 _+ 7.1 pg/ml; p = 
0.01). Patients in the standard group had a higher mean 
pulmonary artery pressure, right ventricular systolic pres- 
sure, and transpulmonary gradient. Linear regression 
analysis howed that faster heart rate, high mean pulmo- 
nary artery pressure, high pulmonary capillary wedge 
pressure, high transpulmonary gradient and higher cyclo- 
sporine trough levels are associated with higher levels of 
BNP (p < 0.05). We found higher levels of BNP in the 
standard group than in the bicaval group. The increased 
BNP was associated with an increase in the right ventric- 
ular afterload, manifested by a raised transpulmonary 
gradient and raised pulmonary capillary wedge pressure 
without overt ventricular failure. We have demonstrated a 
positive correlation between the BNP levels and heart 
rate, which we suppose is another marker for ventricular 
strain. Our findings correlate well with current under- 
standing of BNP physiology. Plasma levels of BNP mainly 
reflect the degree of ventricular afterload. 6 
There was no correlation between left ventricular sys- 
tolic function (echo recorded ejection fraction) and BNP. 
We can assume that BNP levels after transplantation 
reflect predominantly right ventricular and left ventricular 
diastolic function. There was a positive correlation be- 
tween the BNP and trough cyclosporine l vels. Cyclospo- 
rine therapy tends to increase sympathetic activity, and 
this may contribute to posttransplantation pulmonary and 
systemic hypertension i creasing the afterload. Another 
contributor is salt and water retention caused by stimula- 
tion of the renin-angiotensin-aldosterone syst m. It seems 
that the increased production of natriuretic peptides is a 
normal physiologic response to the hypertension and 
increased water and salt retention. Right atrial pressure, 
ejection fraction, serum creatinine, serum electrolytes, 
and the histologic grade of rejection did not show signif- 
icant correlation with raised ANP and BNP after either 
technique of orthotopic heart transplantation. Unlike 
Jahnke and colleagues, we found no correlation between 
cold ischemic time and the release of natriuretic peptides. 
In summary, there is no correlation between atriuretic 
peptide secretion and atrial mass or renal function. Dif- 
ferential regulation of ANP and BNP seems to influence 
the secretion of both hormones after transplantation. 
BNP correlates predominantly with right ventricular per- 
formance and afterload. The bicaval technique seems to 
be associated with better right ventricular performance. 
The ANP vasodilator effect may be a compensatory 
mechanism to the cyclosporine hypertensiv e effect. Mea- 
